The scrutiny follows the company’s August 11, 2026, second-quarter financial report, which revealed that $3.8 million of its $5.5 million total revenue stemmed from one-time licensing milestones rather than core operations. Organic sales for VIZZ stagnated at $1.73 million, reflecting a modest 9% volume growth. The market reaction was immediate; the following day, Bank of America downgraded the stock from "Buy" to "Neutral," slashing its price target from $31.00 to $7.00 due to the lackluster product rollout. Investors who suffered losses are now being urged to contact Danielle Peyton at Pomerantz LLP to discuss potential participation in a class action lawsuit.